RxDoctor Payments Data

Matthew Thompson, DO

Family Medicine · Denton, TXNPI 1619989266

Payments from drug & device makers

$10,291in general payments, 2019–2025

Across 639 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$949
  • Antares Pharma, Inc.$706
  • GSK$553
  • Lilly USA, LLC$527
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$10,18299%
  • Education$1081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)132$1,943
Novo Nordisk74$1,048
AstraZeneca40$949
Antares Pharma, Inc.44$706
GSK31$553
Lilly USA, LLC35$527
Pfizer22$407
Clarus Therapeutics Inc.18$326
Upsher-smith Laboratories LLC19$309
Currax Pharmaceuticals LLC20$282
Amgen14$265
Aytu Biopharma, Inc.25$260
Shield Therapeutics Inc8$176
Axsome Therapeutics, Inc.12$174
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$172
Endo Pharmaceuticals Inc.10$169
Otsuka America Pharmaceutical, Inc.9$168
Tolmar, Inc.15$161
Phathom Pharmaceuticals, Inc.10$132
Biohaven Pharmaceuticals, Inc.6$112
Eisai Inc.6$106
Corcept Therapeutics4$102
Sanofi-aventis U.S. LLC6$100
Merck5$80
Abbott4$80
Boehringer Ingelheim5$76
Takeda Pharmaceuticals U.S.A., Inc.5$76
Halozyme Inc3$66
Ironwood Pharmaceuticals, Inc5$65
Arbor Pharmaceuticals, Inc.4$56
Amarin Pharma, Inc.3$50
Johnson & Johnson3$45
Astellas Pharma US Inc2$41
IBSA Pharma Inc.2$39
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$38
Neos Therapeutics, LP2$36
Idorsia Pharmaceuticals US Inc2$34
Azurity Pharmaceuticals, Inc.2$32
Optinose US, Inc.1$29
Sanofi Pasteur Inc.2$29
Otsuka Pharmaceutical Development & Commercialization, Inc.1$28
Vivus LLC2$25
Paratek Pharmaceuticals, Inc.1$24
Exact Sciences1$23
Inspire Medical Systems, Inc.1$23
Scilex Pharmaceuticals Inc.1$22
Medtronic1$16
Kaleo, Inc.1$16
Biohaven Pharmaceutical Holding Company Ltd.1$15
Acerus Pharmaceuticals Corporation1$14
Teva Pharmaceuticals USA, Inc.1$14
Lundbeck LLC1$14
Verity Pharmaceuticals Inc.1$13
Kowa Pharmaceuticals America, Inc.1$13
Bayer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,291 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$113,712
Medicare patients
198
Services billed
2,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide44$100,726
OzempicSemaglutide47$73,019
FarxigaDapagliflozin Propanediol28$31,083
JardianceEmpagliflozin23$29,857
EliquisApixaban38$29,396
MounjaroTirzepatide17$28,189
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$25,273
VraylarCariprazine Hcl12$25,184
MyrbetriqMirabegron17$16,651
XareltoRivaroxaban14$11,257
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,202
Synjardy XrEmpagliflozin/Metformin Hcl12$7,733
Omeprazole139$3,203
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide81$3,164
Azelastine Hcl65$2,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,048$173,74491 claims
AstraZenecaFarxiga, Breztri Aerosphere$949$41,28542 claims
Boehringer IngelheimJardiance, Synjardy Xr$76$37,59135 claims
PfizerEliquis, Paxlovid$407$30,82550 claims
Lilly USA, LLCMounjaro$527$28,18917 claims
AbbVieVraylar, Synthroid, Armour Thyroid$1,943$27,50664 claims
GSKTrelegy Ellipta$553$25,27314 claims
Astellas Pharma US IncMyrbetriq$41$16,65117 claims
Johnson & JohnsonXarelto$45$11,25714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →